期刊文献+

国产盐酸吉西他滨联合顺铂治疗晚期非小细胞肺癌的临床观察

下载PDF
导出
摘要 目的观察国产盐酸吉西他滨(泽菲)联合顺铂治疗ⅢB~Ⅳ期初治非小细胞肺癌(NSCLC)的临床疗效和不良反应。方法初治的ⅢB~Ⅳ期NSCLC患者38例,采用盐酸吉西他滨(泽菲)1000mg/m2,d1、8,静脉滴注;顺铂100mg/m2,d1~3,静脉滴注;21d为1个周期,按WHO标准进行疗效评价。结果38例患者均可评价疗效,无CR病例,PR病例17例,SD16例,PD5例,有效率(CR+PR)为44.74%(17/38),中位生存期11.6个月,肿瘤进展时间6.8个月。毒副反应主要为胃肠道反应和血液学毒性,Ⅲ~Ⅳ度中性粒细胞下降和血小板下降分别为18.4%和13.2%。结论国产盐酸吉西他滨(泽菲)联合顺铂治疗晚期NSCLC有效率高,有生存优势,毒副作用可耐受。
出处 《基层医学论坛》 2007年第12期1090-1091,共2页 The Medical Forum
  • 引文网络
  • 相关文献

参考文献1

二级参考文献7

  • 1Non-small Cell Lung Cancer Co-operative Group. Chemotherapy in non-small cell lung cancer: a recta-analysis using up-dated data on individual patients from 52 randomized trials [J]. Br Med J, 1995(31 ) :899 -909.
  • 2Sorenson S, Glimelius B, Nygren P. A systematic overview of chemotherapy effects in non-small cell lung cancer [ J ]. Acta Oncol, 2001. 40 (2 -3) : 327 -339.
  • 3Shord SS, Faucette SR, Gillenwater HH, el al. Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer [ J ]. Cancer Chemother Pharmacol. 2003. 51 (4):328-336.
  • 4Asai G, Fukuoka M. Phase Ⅱ sludies of gemcitabine for non-small cell lung cancer in Japan [J]. Gan To Kagaku Rvoho,1999, 26(7) : 884 -889.
  • 5Inoue A, Saijo N. Recent advances in the chemotherapy of non-small Cell lung cancer [J]. Jpn J Clin Oncol, 2001, 31 (7):299 - 304.
  • 6Grigorescu AC, Draghiei IN, Nitipir C, et al. Gemcitabine(GEM) and carboplatin ( CBDCA ) versus cisplatin (CDDP)and vinblastine ( VLB ) in advanced non-small-cell lung cancer (NSCLC) stages Ⅲ and Ⅳ:a phase Ⅲ randomized trial [J].Lung Cancer. 2002. 37( 1 ) :6 - 15.
  • 7Masotti A, Zannini C, Gentile A, et al. Activity of gemcitabine and carboplatin in advanced non-small cell lung cancer: a phase Ⅱ trial [J]. Lung Cancer, 2002, 36( 1 ) :99 - 103.

共引文献13

;
使用帮助 返回顶部